LUBAC and ABIN-1 Modulate TRAIL-Based NF-κB Induction in Human Embryonic Kidney 293 Cells
Sebastian Dörn(Medical University of Vienna), Bernd Jilma(Medical University of Vienna)
Cited by 6
Related Papers
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
|New England Journal of Medicine|2024|151
Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study
|Haematologica|2020|66
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.
|Transplantation|2024|0